Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis;...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Target Price
The average target price of GNFT.PA is 8.6 and suggests 63% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell